stockrow
Saturday 7 November 2026
Export MPLT’s income statement to Excel — free account
MapLight Therapeutics, Inc.
MPLT Healthcare Biotechnology
- EPS
- +96.6%
- Free cash flow
- −31.9%
Quarter to June 2026, against a year earlier
6.86
0.64
+10.29%
Follow MPLT
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 15 | 15 | 15 | 0.0% | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | — | — | (78) | (161) | (230) | +107.7% | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | — | — | — | — | (78) | (161) | (230) | +107.7% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | — | — | (105.38) | (18.56) | (42.31) | (82.4%) | ||||||
| Cash flow | — | — | — | — | — | — | — | — | (107.06) | (15.91) | (3.84) | (85.1%) | ||||||
| Capex | — | — | — | — | — | — | — | — | (1.05) | (0.05) | (0.01) | (94.8%) | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (108.10) | (15.97) | (3.85) | (85.2%) | ||||||
| Book value | — | — | — | — | — | — | — | — | (263.01) | 52.80 | 7.67 | n/m | ||||||
| Shares, m | — | — | — | — | — | — | — | — | 1 | 9 | 25 | +1,079.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | (79) | (138) | (175) | +75.3% | |||||
| Capex | — | — | — | — | — | — | — | — | (1) | 0 | 0 | (38.6%) | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (80) | (139) | (175) | +74.2% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | 99 | 308 | 299 | +212.6% | |||||
| Net debt | — | — | — | — | — | — | — | — | (109) | (305) | (305) | +180.4% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | (194) | 458 | 348 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | 0.00 | (52.29) | (124.79) | (52.3) pt | |||||
| ROIC | — | — | — | — | — | — | — | — | 0.00 | (68.95) | (348.44) | (68.9) pt | ||||||
| ROE | — | — | — | — | — | — | — | — | 0.00 | (121.74) | (297.18) | (121.7) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 109 | 133 | — | +22.0% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 25 Oct 2026
MapLight Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| AVTX Avalo Therapeutics, Inc. | $355.6M | — (loss-making) | — (loss-making) | −70.14% (below 0%: shrinking) | n/m | +75.70% (above 0%: growing) | 55.73% | 0.00% | Compare |
| RZLT Rezolute, Inc. | $352.1M | — (loss-making) | — | — | n/m | +40.23% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CTNM Contineum Therapeutics, Inc. | $345.9M | — (loss-making) | — | — | n/m | +10.04% (above 0%: growing) | 100.00% | 0.00% | Compare |
| MPLT MapLight Therapeutics, Inc. | $345.7M | — (loss-making) | — | — | n/m | −31.91% (below 0%: shrinking) | — | 0.00% | |
| AGMB AgomAb Therapeutics NV | $343.3M | — | — | — | — | — | — | — | Compare |
| SRZN Surrozen, Inc. | $340.9M | — (loss-making) | — (loss-making) | +408.65% (above 0%: growing) | n/m | −21.25% (below 0%: shrinking) | 100.00% | (207.40%) | Compare |
| AVIR Atea Pharmaceuticals, Inc. | $338.5M | — (loss-making) | — (loss-making) | +295.16% (above 0%: growing) | n/m | +85.53% (above 0%: growing) | 0.00% | 0.00% | Compare |
| OBIO Orchestra BioMed Holdings, Inc. | $337.8M | — (loss-making) | — (loss-making) | −89.47% (below 0%: shrinking) | n/m | −25.87% (below 0%: shrinking) | 71.59% | (25,404.55%) | Compare |
| AUTL Autolus Therapeutics PLC Sponsored ADR | $335.4M | — (loss-making) | — (loss-making) | +118.37% (above 0%: growing) | n/m | +67.55% (above 0%: growing) | 55.20% | (95.95%) | Compare |
| Median of peers | $342.1M | — | — | +118.37% | — | +40.23% | 55.73% | 0.00% |
Pay and ownership Proxy statement filed 29 April 2026
Ownership
Directors and executive officers, together
3.80%
Catalyst4, Inc.
47.10%
Novo Holdings A/S
8.80%
Forbion Growth Opportunities Fund III Coöperatief U.A
7.70%
T. Rowe Price Investment Management, Inc.
6.70%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement